LivaNova (NASDAQ:LIVN) Hits New 52-Week High – What’s Next?

LivaNova PLC (NASDAQ:LIVN) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $80.96 and last traded at $80.4150, with a volume of 11296 shares. The stock had previously closed at $79.39.

Analysts Set New Price Targets

Several brokerages have issued reports on LIVN. Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research report on Wednesday, February 25th. Barclays boosted their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Mizuho boosted their price target on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Stock Performance

The firm’s 50-day moving average price is $69.71 and its two-hundred day moving average price is $66.04. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of 40.76 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts expect that LivaNova PLC will post 3.73 EPS for the current fiscal year.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its holdings in LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the period. State of Wyoming purchased a new stake in LivaNova in the 2nd quarter valued at about $31,000. Quarry LP purchased a new stake in LivaNova in the 3rd quarter valued at about $36,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Finally, Covestor Ltd increased its stake in LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after purchasing an additional 392 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.